Archive

Filter

Makeover your portfolio with Cynosure. The company develops non-invasive and minimally invasive aesthetic treatments. Its launch of the SculpSure product (non-invasive laser treatment for fat removal) last September is boosting profits. SculpSure’s  rave reviews and high patient satisfaction is making it popular with doctors.Cynosure’s has sold hyperthermic laser treatments for over 25… Read More

Apogee EnterprisesDemand for Apogee’s (NSDQ: APOG) specialty glass is closely correlated to new commercial buildings. The July Architectural Billings Index (ABI) came in at 51.5, down slightly from June’s level but still above the average for the first six months of the year. New design contract rebounded to 51.8 from… Read More

CrayCray (NSDQ: CRAY) could benefit from one of the largest awards given to academic research for supercomputers this year. The National Science Foundation granted $110 million to The Extreme Science and Engineering Discovery Environment, known as XSEDE for a big data project. That money could be used to buy Cray computers. Read More

NMI Holdings (NSDQ: NMIH) reported second-quarter net income of $2 million, or 3 cents per share, compared to a net loss of $10.4 million, or 18 cents per share, for the same period in 2015. The company benefited from stronger new insurance written that soared 129% to $5.8 billion. Sales… Read More

CrayShares of Cray (NSDQ: CRAY) fell 30% in the first week of August, dropping from $31 to $21.80. On Aug. 2 the company reported greater-than-expected second-quarter losses of 29 cents per share compared to analyst expectations of 26 cents. Revenue of $100 million for the quarter missed analyst expectations of… Read More

The second-quarter earnings season has been rocky. During the past two weeks, almost all the stocks in our Growth Stock Strategist  portfolio reported earnings, and the ensuing changes in stock prices were oddly disconnected from the numbers we analyzed. Although we saw some fabulous performers, marginal earnings misses induced sucker punches while some… Read More

We are selling Express (NYSE: EXPR) out of the Growth Stock Strategist portfolio. The shriveling of mall traffic matched with a poor quarter of merchandising demolished estimates for the year. Earnings for this year are now $.98 versus $1.48 when… Read More

This specialty chemical company has been squeezing more profits from less revenue. A 2014 restructuring that included selling off less profitable lines, introducing more profitable specialized products and closing excess manufacturing capacity, has begun to bear fruit.Earnings more than doubled the first six months of the year and are expected… Read More